Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
930
Trial Sponsor
Clinical Trial Start Date
January 7, 2019
0Primary Completion Date
May 17, 2021
0Study Completion Date
May 17, 2021
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
ARO-ANG30
sterile normal saline (0.9% NaCl)0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients0
Last Updated
September 21, 2021
0Allocation Type
Randomized0
Intervention Model
Sequential Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
